Dendreon Reports Fourth Quarter and 2011 Year End Financial Results
- Conference Call to be Hosted February 27, 2012 at 9:00 a.m. ET/6:00 a.m. PT -
SEATTLE--(BUSINESS WIRE)-- February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.
The net loss for the year ended December 31, 2011 was $337.8 million, or $2.31 per share, compared to $439.5 million, or $3.18 per share for the year ended December 31, 2010. Net income in the fourth quarter of 2011 was $38.1 million or $0.26 per share, compared to a net loss of $91.8 million, or $0.64 per share, for the same period in 2010. The fourth quarter of 2011 included a royalty payment of $125 million associated with the sale of our VICTRELIS™ (boceprevir) royalty interest. Dendreon's total operating expenses, including cost of product revenue, for the year ended December 31, 2011 were $633.3 million compared to $340.2 million in 2010.
As of December 31, 2011, Dendreon had approximately $617.7 million in cash, cash equivalents, and short-term and long-term investments compared to $277.3 million as of December 31, 2010.
Recent Highlights:
Announced the election of John H. Johnson to the position of president and chief executive officer (CEO) and Mitchell H. Gold, MD, as executive chairman, who will serve in that role until June 30, 2012, at which point he will continue to serve as a director and Mr. Johnson will become chairman.
At the end of the fourth quarter, completed in-servicing for more than 840 total sites, of which:
More than 590 sites have infused PROVENGE® (sipuleucel-T).
Approximately 615 sites have either infused the product or have their patients scheduled for their first PROVENGE regimen.
Improved PROVENGE reimbursement landscape for customers and patients:
Reported average time to payment is less than 30 days for physicians, which is better than industry standard, reflecting an improved reimbursement landscape due to a national coverage decision and activation of a Q-code that accelerates electronic adjudication of claims.
The Centers for Medicare and Medicaid Services (CMS) updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE. With this decision, the coverage of PROVENGE is now consistent with all other infused biologics.
A recent analysis suggests that approximately 75% of patients had minimal or no out-of-pocket costs for PROVENGE.
Filed the marketing authorization application (MAA) for PROVENGE with the European Medicines Agency, which was validated in January.
Began enrollment in its clinical study evaluating PROVENGE and abiraterone.
"Dendreon has embraced the challenge of introducing an entirely new treatment paradigm for an entirely new market and has made important progress towards establishing PROVENGE as the foundation of care," said John H. Johnson, president and chief executive officer.
- Conference Call to be Hosted February 27, 2012 at 9:00 a.m. ET/6:00 a.m. PT -
SEATTLE--(BUSINESS WIRE)-- February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.
The net loss for the year ended December 31, 2011 was $337.8 million, or $2.31 per share, compared to $439.5 million, or $3.18 per share for the year ended December 31, 2010. Net income in the fourth quarter of 2011 was $38.1 million or $0.26 per share, compared to a net loss of $91.8 million, or $0.64 per share, for the same period in 2010. The fourth quarter of 2011 included a royalty payment of $125 million associated with the sale of our VICTRELIS™ (boceprevir) royalty interest. Dendreon's total operating expenses, including cost of product revenue, for the year ended December 31, 2011 were $633.3 million compared to $340.2 million in 2010.
As of December 31, 2011, Dendreon had approximately $617.7 million in cash, cash equivalents, and short-term and long-term investments compared to $277.3 million as of December 31, 2010.
Recent Highlights:
Announced the election of John H. Johnson to the position of president and chief executive officer (CEO) and Mitchell H. Gold, MD, as executive chairman, who will serve in that role until June 30, 2012, at which point he will continue to serve as a director and Mr. Johnson will become chairman.
At the end of the fourth quarter, completed in-servicing for more than 840 total sites, of which:
More than 590 sites have infused PROVENGE® (sipuleucel-T).
Approximately 615 sites have either infused the product or have their patients scheduled for their first PROVENGE regimen.
Improved PROVENGE reimbursement landscape for customers and patients:
Reported average time to payment is less than 30 days for physicians, which is better than industry standard, reflecting an improved reimbursement landscape due to a national coverage decision and activation of a Q-code that accelerates electronic adjudication of claims.
The Centers for Medicare and Medicaid Services (CMS) updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE. With this decision, the coverage of PROVENGE is now consistent with all other infused biologics.
A recent analysis suggests that approximately 75% of patients had minimal or no out-of-pocket costs for PROVENGE.
Filed the marketing authorization application (MAA) for PROVENGE with the European Medicines Agency, which was validated in January.
Began enrollment in its clinical study evaluating PROVENGE and abiraterone.
"Dendreon has embraced the challenge of introducing an entirely new treatment paradigm for an entirely new market and has made important progress towards establishing PROVENGE as the foundation of care," said John H. Johnson, president and chief executive officer.
28/2 2012 19:30 Alberto 0
53611 Selv med de sidste blomsterord har regnskabet ikke bekommet markedet godt - jeg har svært ved at gennemskue det, så eneste kommentar er, at BAVA også faldt pladask på samme måde, og altså fortsætter med at korrelere med DNDN. - Måske ikke så mærkeligt endda - men der er nu lang tid til at BAVA kan sammenligne sig direkte med konkurrenten!
A
A
28/2 2012 20:53 fistandanti 053616 DNDN fik primært hug på baggrund af forventningen om en lavere en-cifret vækstrate i Q1. Dette pga. flere patienter søgte behandling inden årsskiftet og jule-helligdagene, hvorfor væksten her også var større en først forventet.
Nu er det spændende at se hvor DNDN bunder henne, det går som regel vildt for sig, når den skal staffes...
http://seekingalpha.com/article/395701-dendreon-s-ceo-discusses-q4-2011-results-earnings-conference-call?source=yahoo
Nu er det spændende at se hvor DNDN bunder henne, det går som regel vildt for sig, når den skal staffes...
http://seekingalpha.com/article/395701-dendreon-s-ceo-discusses-q4-2011-results-earnings-conference-call?source=yahoo
